Zynteglo
Zynteglo halt re-ignites viral vector safety concerns; analysts
Phil Taylor
beta thalassaemia, bluebird bio, cancer, gene therapy, lentivector, Oxford Biomedica, safety, Zynteglo
0 Comment
X
Zynteglo halt re-ignites viral vector safety concerns; analysts
https://pharmaphorum.com/news/zynteglo-halt-re-ignites-viral-vector-safety-concerns-analysts/
bluebird bio ‘baffled’ after NICE rejects beta-thalassaemia gene therapy
Richard Staines
beta thalassaemia, bluebird bio, gene therapy, Haematology, NICE, Zynteglo
0 Comment
X
bluebird bio ‘baffled’ after NICE rejects beta-thalassaemia gene therapy
https://pharmaphorum.com/news/bluebird-bio-baffled-after-nice-rejects/
bluebird offers instalment payments for Zynteglo gene therapy
Phil Taylor
bluebird bio, gene therapy, thalassaemia, Zynteglo
0 Comment
X
bluebird offers instalment payments for Zynteglo gene therapy
https://pharmaphorum.com/news/bluebird-offers-instalment-payments-for-zynteglo-gene-therapy/
bluebird claims first approval for gene therapy Zynteglo in EU
Phil Taylor
beta thalassaemia, bluebird bio, gene therapy, Zynteglo
0 Comment
X
bluebird claims first approval for gene therapy Zynteglo in EU
https://pharmaphorum.com/news/bluebird-claims-first-approval-for-gene-therapy-zynteglo-in-eu/
X
bluebird bio gets CHMP nod for gene therapy Zynteglo
https://pharmaphorum.com/news/bluebird-bio-gets-chmp-nod-for-gene-therapy-zynteglo/